BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So just to kind of summarize what it is, this is a phase three study randomized for patients with muscle invasive urethelial carcinoma who undergo radical surgery and they have high risk disease. And by high risk disease, This means they received neoadjuvant cisplatinibase chemotherapy and have a persistent T2 muscle invasive disease or greater.
0
💬
0
Comments
Log in to comment.
There are no comments yet.